双氯芬酸钠对大鼠骨髓间充质干细胞影响的浓度、时间效应

目的通过不同浓度的双氯芬酸钠干预体外培养的大鼠骨髓间充质干细胞(bone marrow mesenchymal stem cells,BMSCs),观察其对大鼠骨髓间充质干细胞增殖、凋亡及成骨分化能力的影响;不同药物干预时间对细胞成骨分化能力的影响。方法不同浓度的双氯芬酸钠(6.4、3.2、1.6、0.8、0.4mg/L)干预第4代(P4)BMSCs,通过MTS法检测细胞增殖活性;AnnexinⅤ-FITC法检测细胞凋亡;根据茜素红染色钙结节的数量,初步检测细胞成骨能力。并选取1.6mg/L的药物浓度,不同时间点和时长进行干预,检测细胞成骨分化能力的变化。结果随着双氯芬酸钠浓度的升高,BMSCs细胞增殖活性逐渐降低,细胞凋亡比率升高,钙结节数量减少。药物在第1~14天期间干预能够减少钙结节的形成,在第14~21天期间干预对钙结节的形成无明显影响。结论双氯芬酸钠可影响BMSCs的增殖、凋亡及成骨分化能力,且呈浓度和时间依赖性,短期的作用效果是部分可逆的。     

高脂血症大鼠模型建立的动态研究

目的 建立高脂血症大鼠模型,比较各时间点大鼠的血脂水平,为更合理的使用高脂血症动物模型提供依据.方法 将96只sD大鼠随机分为普通饲料喂养组及高脂饲料喂养组(高脂饲料喂养组根据处死时间分为ld、2d、3d、4d、5d、6d、7d、14d、21d、28d、35d共11个亚组),每组8只大鼠.分别于相应时间点,对各组大鼠采...     

医院内缺血性脑卒中患者静脉溶栓时间及预后分析

目的: 比较医院内卒中与医院外卒中患者静脉溶栓治疗时间的差异以及医院内卒中患者预后的影响因素。方法: 回顾性分析2017年6月至2018年9月在浙江省71家医院接受静脉溶栓治疗的3050例缺血性脑卒中患者的临床资料。比较医院内卒中（101例）与医院外卒中（2949例）患者溶栓治疗各时间点的差异,并采用二元Logistic回归分析法分析医院内卒中患者静脉溶栓治疗3个月预后的影响因素。结果: 医院内卒中患者比医院外卒中患者的入院至影像时间长[53.5（32.0,79.8）min vs 20.0（14.0,28.0）min,P < 0.01]、影像至溶栓时间长[47.5（27.3,64.0）min vs 36.0（24.0,53.0）min,P < 0.01]、入院至溶栓时间长[99.0（70.5,140.5）min vs 55.0（41.0,74.0）min,P < 0.01]。在医院内卒中患者中,高级卒中中心比初级卒中中心入院至影像时间更长[59.5（44.5,83.3）min vs 37.5（16.5,63.5）min,P < 0.01],入院至溶栓时间更长[110.0（77.0,145.0）min vs 88.0（53.8,124.3）min,P < 0.05],但影像至溶栓时间更短[36.5（23.8,60.3）min vs 53.5（34.3,64.8）min,P < 0.05]。二元Logistic回归分析结果显示,年龄（OR=0.934,95%CI：0.882~0.989,P < 0.05）和基线美国国立卫生研究院卒中量表（NIHSS）评分（OR=0.912,95%CI：0.855~0.973,P < 0.01）是医院内卒中患者静脉溶栓治疗3个月预后的独立影响因素。结论: 与医院外卒中相比,医院内卒中存在一定延误,未来需要建立更加流畅的医院内卒中溶栓流程。     

标本保存时间和温度对活化部分凝血活酶时间测定的影响分析

目的分析标本保存时间和温度对活化部分凝血活酶时间(APTT)测定的影响.方法选择180例门诊患者标本,分3组,用Sysmex CA1500全自动血凝分析仪及其配套试剂,分别检测抗凝血标本全血室温(26℃)放置、离心后在室温(26℃)及冰箱(4℃)保存条件下0,2,4,6,8 h的APTT结果,各结果分别与各组0 h结果比较.结果标本全血室温(26℃)放置,离心后室温(26℃)或冰箱(4℃)放置6 hAPTT结果与0h相比差异有统计学意义(P<0.05).结论在本实验室检测未使用抗凝药物的患者的APTT标本时,离心或未离心的标本在未开盖的试管中保存在4℃或室温的条件下,应在标本采集后4 h内检测.     

The Influence of Varying Precompaction and Main Compaction Profile Parameters on the Mechanical Strength of Compacts

The purpose of this work was to investigate how altering the method of force application could be beneficial to tablet production in order to increase tablet strength and eliminate or minimize the incidence of capping and lamination. An integrated compaction research system (i.e., compaction simulator) was used throughout this study. Compaction profiles containing a single compaction event and a double (pre- and main) compaction event were created. The ratio and magnitude of the pre- and main compaction pressures were varied and the time interval between the pre- and main compaction events was altered to determine the effects on the crushing strengths and capping tendency of the final compacts. In all cases, for a given pressure, the double compaction event produced stronger tablets than the single compaction event. When the ratio and magnitude of the pre- and main compaction pressures were varied, the results differed depending on the material undergoing compaction. Dicalcium phosphate/microcrystalline cellulose and pregelatinized starch tablets had no significant difference in crushing strength values regardless of whether the precompaction pressure was less than or greater than the main compaction pressure. However, both direct compression (DC) acetaminophen and DC ibuprofen were found to have increased crushing strengths and decreased capping/lamination when the precompaction pressure was less than the main compaction pressure. When the time interval between the pre- and main compaction events was varied from 30 to 500 msec, no significant difference in the crushing strength or capping/lamination tendency was observed. It was concluded that the effect of altering the ratio and magnitude of the pre- and main compaction pressures varied from one material to another, suggesting that the profiles should be tailored individually for the specific material undergoing compaction.     

Starch digestibility modulation significantly improves glycemic variability in type 2 diabetic subjects: A pilot study

Background and aimsIn type 2 diabetes (T2D) patients, the reduction of glycemic variability and postprandial glucose excursions is essential to limit diabetes complications, beyond HbA1c level. This study aimed at determining whether increasing the content of Slowly Digestible Starch (SDS) in T2D patients’ diet could reduce postprandial hyperglycemia and glycemic variability compared with a conventional low-SDS diet.Methods and resultsFor this randomized cross-over pilot study, 8 subjects with T2D consumed a controlled diet for one week, containing starchy products high or low in SDS. Glycemic variability parameters were evaluated using a Continuous Glucose Monitoring System.Glycemic variability was significantly lower during High-SDS diet compared to Low-SDS diet for MAGE (Mean Amplitude of Glycemic Excursions, p < 0.01), SD (Standard Deviation, p < 0.05), and CV (Coefficient of Variation, p < 0.01). The TIR (Time In Range) [140–180 mg/dL[ was significantly higher during High-SDS diet (p < 0.0001) whereas TIRs ≥180 mg/dL were significantly lower during High-SDS diet. Post-meals tAUC (total Area Under the Curve) were significantly lower during High-SDS diet.ConclusionOne week of High-SDS Diet in T2D patients significantly improves glycemic variability and reduces postprandial glycemic excursions. Modulation of starch digestibility in the diet could be used as a simple nutritional tool in T2D patients to improve daily glycemic control.Registration numberin clinicaltrials.gov: NCT 03289494.